Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Altamura

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Chemmedchem|April 11, 2008
alpha,alpha-Cyclopentaneglycine dipeptides capped with biaryls as tachykinin NK(2) receptor antagonistsMarina Porcelloni, Piero D'Andrea, Cristina Rossi, et al.
F1000Research|November 8, 2024
A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparisonRoberta Antonelli, Vittoria Forconi, Eleonora Molesti, et al.
European Journal of Pharmacology|March 27, 2004
Mutagenesis at the human tachykinin NK(2) receptor to define the binding site of a novel class of antagonistsStefania Meini, Francesca Bellucci, Claudio Catalani, et al.
Bioorganic & Medicinal Chemistry Letters|February 16, 2011
hNK2 receptor antagonists. The use of intramolecular hydrogen bonding to increase solubility and membrane permeabilityAlessandro Ettorre, Piero D'Andrea, Sandro Mauro, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2002
Insertion of 2-carboxysuccinate and tricarballylic acid fragments into cyclic-pseudopeptides: new antagonists for the human tachykinin NK-2 receptorNicholas J S Harmat, Danilo Giannotti, Rossano Nannicini, et al.
European Journal of Pharmacology|September 19, 2006
MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonistCecilia Cialdai, Manuela Tramontana, Riccardo Patacchini, et al.
European Journal of Pharmacology|June 1, 2005
Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptorStefania Meini, Claudio Catalani, Francesca Bellucci, et al.
Journal of Medicinal Chemistry|April 23, 2010
Structure-activity relationships of 6-methyl-benzo[b]thiophene-2-carboxylic acid (1-[(S)-1-benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl]cyclopentyl)amide, potent antagonist of the neurokinin-2 receptorDaniela Fattori, Marina Porcelloni, Piero D'Andrea, et al.
Children (Basel, Switzerland)|September 28, 2023
Natural Course of <i>IQSEC2</i>-Related Encephalopathy: An Italian National Structured SurveySilvia Leoncini, Lidia Boasiako, Diego Lopergolo, et al.
Human Vaccines & Immunotherapeutics|January 28, 2026
Unexpectedly competent immune response to SARS-CoV-2 vaccination in Rett syndromeLudovica Soldateschi, Silvia Leoncini, Fabio Fiorino, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Chemmedchem|April 11, 2008
alpha,alpha-Cyclopentaneglycine dipeptides capped with biaryls as tachykinin NK(2) receptor antagonistsMarina Porcelloni, Piero D'Andrea, Cristina Rossi, et al.
F1000Research|November 8, 2024
A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparisonRoberta Antonelli, Vittoria Forconi, Eleonora Molesti, et al.
European Journal of Pharmacology|March 27, 2004
Mutagenesis at the human tachykinin NK(2) receptor to define the binding site of a novel class of antagonistsStefania Meini, Francesca Bellucci, Claudio Catalani, et al.
Bioorganic & Medicinal Chemistry Letters|February 16, 2011
hNK2 receptor antagonists. The use of intramolecular hydrogen bonding to increase solubility and membrane permeabilityAlessandro Ettorre, Piero D'Andrea, Sandro Mauro, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2002
Insertion of 2-carboxysuccinate and tricarballylic acid fragments into cyclic-pseudopeptides: new antagonists for the human tachykinin NK-2 receptorNicholas J S Harmat, Danilo Giannotti, Rossano Nannicini, et al.
European Journal of Pharmacology|September 19, 2006
MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonistCecilia Cialdai, Manuela Tramontana, Riccardo Patacchini, et al.
European Journal of Pharmacology|June 1, 2005
Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptorStefania Meini, Claudio Catalani, Francesca Bellucci, et al.
Journal of Medicinal Chemistry|April 23, 2010
Structure-activity relationships of 6-methyl-benzo[b]thiophene-2-carboxylic acid (1-[(S)-1-benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl]cyclopentyl)amide, potent antagonist of the neurokinin-2 receptorDaniela Fattori, Marina Porcelloni, Piero D'Andrea, et al.
Children (Basel, Switzerland)|September 28, 2023
Natural Course of <i>IQSEC2</i>-Related Encephalopathy: An Italian National Structured SurveySilvia Leoncini, Lidia Boasiako, Diego Lopergolo, et al.
Human Vaccines & Immunotherapeutics|January 28, 2026
Unexpectedly competent immune response to SARS-CoV-2 vaccination in Rett syndromeLudovica Soldateschi, Silvia Leoncini, Fabio Fiorino, et al.
Pageof 5